Abstract: The invention relates to a structural protein of adeno-associated virus (AAV) which comprises at least one mutation which brings about an increase in the infectivity of the virus.
Type:
Application
Filed:
December 1, 2009
Publication date:
March 3, 2011
Applicant:
MEDIGENE AKTIENGESELLSCHAFT
Inventors:
Michael Hallek, Martin Ried, Gilbert Deleage, Anne Girod
Abstract: The invention relates to a scleroprotein of an adeno-associated virus which contains at least one mutation. Said mutation causes the chromatographic properties to be modified. The invention also relates to the production of said scleroprotein and the use thereof.
Type:
Application
Filed:
September 24, 2007
Publication date:
April 29, 2010
Applicant:
MEDIGENE AKTIENGESELLSCHAFT
Inventors:
Michael Hallek, Anne Girod, Martin Ried, Christof Stolla, Ulrich Moebius
Abstract: The invention relates to a scleroprotein of an adeno-associated virus which contains at least one mutation. Said mutation causes the chromatographic properties to be modified. The invention also relates to the production of said scleroprotein and the use thereof.
Type:
Application
Filed:
September 24, 2007
Publication date:
October 1, 2009
Applicant:
MEDIGENE AKTIENGESELLSCHAFT
Inventors:
Michael Hallek, Anne Girod, Martin Ried, Christof Stolla, Ulrich Moebius
Abstract: The invention relates to a scleroprotein of an adeno-associated virus which contains at least one mutation. Said mutation causes the chromatographic properties to be modified. The invention also relates to the production of said scleroprotein and the use thereof.
Type:
Application
Filed:
September 24, 2007
Publication date:
April 16, 2009
Applicant:
MEDIGENE AKTIENGESELLSCHAFT
Inventors:
Michael HALLEK, Anne GIROD, Martin RIED, Christof STOLLA, Ulrich MOEBIUS
Abstract: The invention relates to a structural protein of adeno-associated virus (AAV) which comprises at least one mutation which brings about an increase in the infectivity of the virus.
Type:
Grant
Filed:
June 21, 1999
Date of Patent:
January 1, 2008
Assignee:
Medigene Aktiengesellschaft
Inventors:
Michael Hallek, Martin Ried, Gilbert Deleage, Anne Girod
Abstract: The invention relates to a scleroprotein of an adeno-associated virus which contains at least one mutation. Said mutation causes the chromatographic properties to be modified. The invention also relates to the production of said scleroprotein and the use thereof.
Type:
Grant
Filed:
July 18, 2000
Date of Patent:
October 23, 2007
Assignee:
MediGene Aktiengesellschaft
Inventors:
Michael Hallek, Anne Girod, Martin Ried, Christof Körner, Ulrich Moebius
Abstract: The invention relates to a structural protein of adeno-associated virus (AAV) which comprises at least one mutation which brings about an increase in the infectivity of the virus.
Type:
Application
Filed:
December 28, 2006
Publication date:
October 11, 2007
Applicant:
MEDIGENE AKTIENGESELLSCHAFT
Inventors:
Michael Hallek, Martin Ried, Gilbert Deleage, Anne Girod
Abstract: The invention relates to processes for preparing oxiranecarboxylic acids and derivatives thereof, in particular to processes which proceed under stereochemical control of the reaction steps, to the oxiranecarboxylic acids prepared according to the invention and derivatives thereof and to their use in pharmaceutical compositions, in particular for treating hyperlipaemia.
Abstract: The invention relates to a medicament for preventing or treating human papilloma virus (HPV)-specific tumors containing at least one fusion protein and optional suitable additives and/or auxiliary agents. Said fusion protein is comprised of at least one L1-protein of one or more papilloma viruses, and is also comprised of at least one E-protein of one or more papilloma viruses, whereby the fusion protein does not contain any papilloma virus non-specific epitopes.
Abstract: The present invention relates to a papillomavirus T-cell epitope having an amino acid sequence AQIFNKPYW, AGVDNRECI and/or to a functionally active variant thereof, also to their use in diagnostics and therapy.
Abstract: The present invention relates to a method for producing a recombinant adeno-associated virus (rAAV), in which at different times a helper construct and also a vector construct are introduced into a suitable cell, and preferably the helper construct does not comprise, in particular with the exception of the AAV promoters, any nucleic acid sequences to which at least a Rep protein can essentially specifically bind and preferably the vector construct comprises ITR sequences in flop orientation. The recombinant adeno-associated viruses produced according to the method of the invention are suitable in particular for producing a tumor cell into which additionally nucleic acids coding for GM-CSF and B7.2 has been introduced, which in turn can be used in the form of a medicament for the treatment of cancers.
Abstract: The present invention relates to a papillomavirus T-cell epitope having an amino acid sequence ILVPKVSGL (SEQ ID NO: 1), RLVWACVGV (SEQ ID NO: 2), HLFNRAGTV (SEQ ID NO: 3), YLRREQMFV (SEQ ID NO: 4), TLQANKSEV (SEQ ID NO: 5), ILEDWNFGL (SEQ ID NO: 6), SLWLPSEATVYL (SEQ ID NO: 7), NLASSNYFPT (SEQ ID NO: 8), TLTADVMTYI (SEQ ID NO: 9), YLPPVPSKV (SEQ ID NO: 10), YDLQFIFQL (SEQ ID NO: 11), ICWGNQLFV (SEQ ID NO: 12), FYNPDTQRL (SEQ ID NO: 13), MHGDTPTLH (SEQ ID NO: 14), ETTDLYCY (SEQ ID NO: 15), QAEPDRAHYN (SEQ ID NO: 16), SMVTSDAQI (SEQ ID NO: 17), and/or to a functionally active variant thereof, and also to their use in diagnostics and therapy.
Abstract: A skin test for detecting the immune status with respect to the transforming virus proteins E6 and E7 of human papilloma viruses is provided. The skin test comprises a diagnosis kit containing an effective amount of the protein E6 and/or E7 or at least an immunologically effective portion of E6 and/or E7. The skin test is carried out by intracutaneously applying the protein E6/E7 of the diagnosis kit and visually inspecting the respective skin region to detect reddening.
Type:
Grant
Filed:
June 20, 2000
Date of Patent:
November 12, 2002
Assignee:
Medigene Aktiengesellschaft Gesellschaft fur
Molekularbiologische Kardiologie und Onkologie
Abstract: The invention relates to a process for separating viruses of different sizes, with the virus-containing solution preferably being filtered through one or more filter membranes.
Type:
Grant
Filed:
December 22, 1999
Date of Patent:
November 12, 2002
Assignee:
MediGene Aktiengesellschaft
Inventors:
Christoph Bogedain, Gerhard Maass, Markus Hörer